Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the efficacy and tolerability of dapagliflozin as an add-on or a switch therapy to lobegli-tazone plus metformin (MFM) in Korean patients with inadequately controlled type 2 diabetes mellitus (T2DM) in real-worldclinical practice. Materials and Methods: The study included 109 patients who started dapagliflozin as add-on or switch therapy to lobeglitazoneplus MFM. The primary outcome was a change in glycated hemoglobin (HbA1c) level from baseline after 12 months of treatment. Secondary outcomes included changes in fasting plasma glucose (FPG), lipid profiles, body weight, visceral fat area (VFA), andblood pressure after 12 months of treatment. Results: The baseline HbA1c was 8.3±1.3% (8.7±1.5% in the add-on group and 8.1±1.0% in the switch group). After 12 months,mean HbA1c decreased (-0.91%) in all patients (p<0.05) (-1.39% in the add-on group and -0.63% in the switch group). Significantreductions in FPG were also observed in both the add-on and switch groups (-54.37 mg/dL and -24.68 mg/dL, respectively). Over-all, there was a significant improvement in serum triglyceride (-24.74 mg/dL), low density lipoprotein cholesterol (-7.92 mg/dL),body weight (-2.98 kg), VFA (-9.00 cm2), and systolic blood pressure (-8.67 mm Hg). Approximately 35.8% of patients achievedHbA1c <7.0% after 12 months. Conclusion: Dapagliflozin, as an add-on or a switch therapy to lobeglitazone plus MFM, can be a suitable alternative for Korean pa-tients with inadequately controlled T2DM. The combination therapy resulted in significant reductions in HbA1c levels, body weight,and blood pressure.
Abstract
Purpose: This study aimed to evaluate the efficacy and tolerability of dapagliflozin as an add-on or a switch therapy to lobegli-tazone plus metformin (MFM) in Korean patients with inadequately controlled type 2 diabetes mellitus (T2DM) in real-worldclinical practice. Materials and Methods: The study included 109 patients who started dapagliflozin as add-on or switch therapy to lobeglitazoneplus MFM. The primary outcome was a change in glycated hemoglobin (HbA1c) level from baseline after 12 months of treatment. Secondary outcomes included changes in fasting plasma glucose (FPG), lipid profiles, body weight, visceral fat area (VFA), andblood pressure after 12 months of treatment. Results: The baseline HbA1c was 8.3±1.3% (8.7±1.5% in the add-on group and 8.1±1.0% in the switch group). After 12 months,mean HbA1c decreased (-0.91%) in all patients (p<0.05) (-1.39% in the add-on group and -0.63% in the switch group). Significantreductions in FPG were also observed in both the add-on and switch groups (-54.37 mg/dL and -24.68 mg/dL, respectively). Over-all, there was a significant improvement in serum triglyceride (-24.74 mg/dL), low density lipoprotein cholesterol (-7.92 mg/dL),body weight (-2.98 kg), VFA (-9.00 cm2), and systolic blood pressure (-8.67 mm Hg). Approximately 35.8% of patients achievedHbA1c <7.0% after 12 months. Conclusion: Dapagliflozin, as an add-on or a switch therapy to lobeglitazone plus MFM, can be a suitable alternative for Korean pa-tients with inadequately controlled T2DM. The combination therapy resulted in significant reductions in HbA1c levels, body weight,and blood pressure.
참고문헌 (25)
- Buse JB, "2019 update to : management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)", Diabetes Care, 43, pp.487~493 (2020)
- Lebovitz HE, "Thiazolidinediones : the forgotten diabetes medications", Curr Diab Rep, 19, pp.151~ (2019)
- van Baar MJB, "SGLT2 inhibitors in combination therapy : from mechanisms to clinical considerations in type 2 diabetes management", Diabetes Care, 41, pp.1543~1556 (2018)
- Kim SG, "Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks : a multicenter, randomized, double-blind, parallel-group, placebo controlled trial", PLoS One, 9, pp.e92843~ (2014)
- Jin SM, "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes : a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension", Diabetes Obes Metab, 17, pp.599~602 (2015)
- American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021", Diabetes Care, 44(Suppl 1), pp.S111~S1124 (2021)
- Nelinson DS, "SGLT2 inhibitors : a narrative review of efficacy and safety", J Osteopath Med, 121, pp.229~239 (2021)
- Blevins T, "Combination therapy for patients with uncontrolled type 2 diabetes mellitus : adding empagliflozin to pioglitazone or pioglitazone plus metformin", Expert Opin Drug Saf, 14, pp.789~793 (2015)
- Kovacs CS, "Empagliflozin improves glycaemic and weight control as addon therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes : a 24-week, randomized, placebo-controlled trial", Diabetes Obes Metab, 16, pp.147~158 (2014)
- 홍아람, "Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice", Diabetes and Metabolism Journal, 43(5), pp.590~606 (2019), 대한당뇨병학회[DOI]
- Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
- Cruz-Jentoft AJ, "Sarcopenia : European consensus on definition and diagnosis : report of the European Working Group on sarcopenia in older people", Age Ageing, 39, pp.412~423 (2010)
- Akinmokun A, "The short insulin tolerance test for determination of insulin sensitivity : a comparison with the euglycaemic clamp", Diabet Med, 9, pp.432~437 (1992)
- Kim SK, "Ratio of waist-to-calf circumference and carotid atherosclerosis in Korean patients with type 2 diabetes", Diabetes Care, 34, pp.2067~2071 (2011)
- Kovacs CS, "Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus", Clin Ther, 37, pp.1773~1788.e1 (2015)[DOI]
- Forst T, "Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone", Diabetes Obes Metab, 16, pp.467~477 (2014)
- Rosenstock J, "Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy", Diabetes Care, 35, pp.1473~1478 (2012)
- Rosenstock J, "Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy : a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin", Diabetes Care, 38, pp.376~383 (2015)
- DeFronzo RA, "Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin", Diabetes Care, 38, pp.384~393 (2015)
- Kosiborod M, "Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs : the CVD-REAL 2 study", J Am Coll Cardiol, 71, pp.2628~2639 (2018)
- Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
- Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
- Mahaffey KW, "Canagliflozin for primary and secondary prevention of cardiovascular events : results from the CANVAS program(Canagliflozin Cardiovascular Assessment Study)", Circulation, 137, pp.323~334 (2018)
- Yki-Järvinen H, "Thiazolidinediones", N Engl J Med, 351, pp.1106~1118 (2004)
- Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial", Lancet, 366, pp.1279~1289 (2005)